Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):261–267. doi: 10.1158/1055-9965.EPI-14-0923

Table 3.

Odds ratios and 95% confidence intervals for the association between metabolic syndrome and endometrial cancer subtype, SEER-Medicare.

Metabolic conditions Endometrioid Grade 1–2 (n=5,516) Endometrioid Grade 3 (n=1,478) Adenocarcinoma (n=5,219)
n % ORa 95% CI n % ORa 95% CI n % ORa 95% CI
 Overweight/obesity 435 7.9 2.08 1.86 – 2.34 106 7.2 1.93 1.56 – 2.38 277 5.3 1.89 1.64 – 2.17
 Impaired fasting glucose 1,551 28.1 1.36 1.27 – 1.46 400 27.1 1.28 1.14 – 1.45 1,160 22.2 1.33 1.24 – 1.44
 High blood pressure 3,877 70.3 1.33 1.25 – 1.42 1,055 71.4 1.37 1.22 – 1.55 3,349 64.2 1.40 1.31 – 1.50
 High triglycerides 2,431 44.1 1.20 1.13 – 1.28 608 41.1 1.11 0.99 – 1.24 1,558 29.9 1.22 1.14 – 1.31
Metabolic syndromeb
 NCEP-III 987 17.9 1.42 1.31 – 1.53 260 17.6 1.40 1.21 – 1.61 561 10.8 1.41 1.27 – 1.56
 IDF 303 5.5 2.09 1.83 – 2.40 73 4.9 2.02 1.57 – 2.59 165 3.2 1.99 1.67 – 2.38
Metabolic conditions Serous (n=1,111) Clear cell (n=291) Mucinous (n=206)
n % ORa 95% CI n % ORa 95% CI n % ORa 95% CI
 Overweight/obesity 76 6.8 1.85 1.45 – 2.36 17 5.8 1.68 1.01 – 2.77 17 8.3 2.71 1.63 – 4.49
 Impaired fasting glucose 336 30.2 1.45 1.27 – 1.67 86 29.6 1.39 1.07 – 1.81 48 23.3 1.21 0.87 – 1.69
 High blood pressure 744 67.0 1.12c 0.98 – 1.28 210 72.2 1.42 1.09 – 1.85 149 72.3 1.74 1.27 – 2.38
 High triglycerides 439 39.5 1.19 1.05 – 1.36 104 35.7 1.06 0.82 – 1.38 80 38.8 1.42 1.05 – 1.92
Metabolic syndromeb
 NCEP-III 192 17.3 1.41 1.19 – 1.67 50 17.2 1.46 1.06 – 2.02 33 16.0 1.69 1.14 – 2.50
 IDF 61 5.5 2.29 1.74 – 3.01 13 4.5 2.03 1.15 – 3.60 15 7.3 4.06c 2.36 – 6.99
Metabolic conditions Carcinosarcoma (n=912) Sarcoma (n=237) Other (n=816) p-het
n % ORa 95% CI n % ORa 95% CI n % ORa 95% CI
 Overweight/obesity 64 7.0 1.87 1.43 – 2.45 17 7.2 1.89 1.14 – 3.13 64 7.8 2.07 1.58 – 2.71 0.82
 Impaired fasting glucose 245 26.9 1.20 1.03 – 1.40 59 24.9 1.16 0.85 – 1.57 255 31.3 1.43 1.23 – 1.67 0.35
 High blood pressure 638 70.0 1.23 1.06 – 1.43 165 69.6 1.33 1.00 – 1.78 571 70.0 1.09 0.93 – 1.28 0.12
 High triglycerides 311 34.1 0.89c 0.76 – 1.03 84 35.4 0.92 0.69 – 1.22 322 39.5 0.93c 0.80 – 1.08 < 0.01
Metabolic syndromeb
 NCEP-III 137 15.0 1.14 0.94 – 1.38 39 16.5 1.34 0.94 – 1.92 151 18.5 1.31 1.08 – 1.58 0.82
 IDF 37 4.1 1.58 1.12 – 2.24 13 5.5 2.17 1.22 – 3.85 49 6.0 2.34 1.72 – 3.17 0.31
a

ORs adjusted for diagnosis date, age, race/ethnicity, registry area, and tobacco use.

b

NCEP-III: US National Cholesterol Education Program Adult Treatment Panel III defines metabolic syndrome as the presence of at least three of the following conditions: central adiposity/elevated waist circumference, hypertension, high triglycerides, low HDL cholesterol, and impaired fasting glucose; IDF: International Diabetes Foundation defines metabolic syndrome as the presence of central adiposity/elevated waist circumference plus any 2 of the other factors (impaired fasting glucose, hypertension, low HDL cholesterol, high triglycerides).

c

p-value <0.05 for pairwise comparison with low grade (1 or 2) endometrioid type tumors.